{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:12:44Z","timestamp":1792203164228,"version":"4.4.0"},"reference-count":195,"publisher":"The Microbiological Society of Korea","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["2021R1F1A1063240"],"award-info":[{"award-number":["2021R1F1A1063240"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Microbiol."],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s12275-024-00159-4","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T13:02:01Z","timestamp":1721653321000},"page":"491-509","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Adenoviral Vector System: A Comprehensive Overview of Constructions, Therapeutic Applications and Host Responses"],"prefix":"10.71150","volume":"62","author":[{"given":"Anyeseu","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7195-9185","authenticated-orcid":false,"given":"Jeong Yoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4586","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"159_CR1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/0022-2836(85)90374-2","volume":"184","author":"K Abremski","year":"1985","unstructured":"Abremski, K., & Hoess, R. (1985). Phage P1 Cre-loxP site-specific recombination: Effects of DNA supercoiling on catenation and knotting of recombinant products. Journal of Molecular Biology, 184, 211\u2013220.","journal-title":"Journal of Molecular Biology"},{"key":"159_CR2","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/0022-2836(92)90623-R","volume":"226","author":"DE Adams","year":"1992","unstructured":"Adams, D. E., Bliska, J. B., & Cozzarelli, N. R. (1992). Cre-lox recombination in Escherichia coli cells mechanistic differences from the in vitro reaction. Journal of Molecular Biology, 226, 661\u2013673.","journal-title":"Journal of Molecular Biology"},{"key":"159_CR3","doi-asserted-by":"publisher","first-page":"16030","DOI":"10.1038\/mtm.2016.30","volume":"3","author":"S Afkhami","year":"2016","unstructured":"Afkhami, S., Yao, Y., & Xing, Z. (2016). Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens. Molecular Therapy Methods & Clinical Development, 3, 16030.","journal-title":"Molecular Therapy Methods & Clinical Development"},{"key":"159_CR4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S1473-3099(21)00128-6","volume":"22","author":"MO Afolabi","year":"2022","unstructured":"Afolabi, M. O., Ishola, D., Manno, D., Keshinro, B., Bockstal, V., Rogers, B., Owusu-Kyei, K., Serry-Bangura, A., Swaray, I., Lowe, B., et al. (2022). Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: A randomised, double-blind, controlled trial. The Lancet Infectious Diseases, 22, 110\u2013122.","journal-title":"The Lancet Infectious Diseases"},{"key":"159_CR5","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/s41417-023-00597-z","volume":"30","author":"SE Ahmadi","year":"2023","unstructured":"Ahmadi, S. E., Soleymani, M., Shahriyary, F., Amirzargar, M. R., Ofoghi, M., Fattahi, M. D., & Safa, M. (2023). Viral vectors and extracellular vesicles: Innate delivery systems utilized in CRISPR\/Cas-mediated cancer therapy. Cancer Gene Therapy, 30, 936\u2013954.","journal-title":"Cancer Gene Therapy"},{"key":"159_CR6","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3390\/cancers10060178","volume":"10","author":"R Aloni-Grinstein","year":"2018","unstructured":"Aloni-Grinstein, R., Charni-Natan, M., Solomon, H., & Rotter, V. (2018). p53 and the viral connection: Back into the future. Cancers, 10, 178.","journal-title":"Cancers"},{"key":"159_CR7","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nature02871","volume":"431","author":"V Ambros","year":"2004","unstructured":"Ambros, V. (2004). The functions of animal microRNAs. Nature, 431, 350\u2013355.","journal-title":"Nature"},{"key":"159_CR8","unstructured":"Anchim, A. (2016). Vaccination potential of adenoviral vectors displaying heterologous epitopes in their capsid proteins (NNT : 2016SACLS070). [Doctoral dissertation, Universit\u00e9 Paris Saclay]."},{"key":"159_CR9","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1126\/science.256.5058.808","volume":"256","author":"WF Anderson","year":"1992","unstructured":"Anderson, W. F. (1992). Human gene therapy. Science, 256, 808\u2013813.","journal-title":"Science"},{"key":"159_CR10","doi-asserted-by":"publisher","first-page":"5915","DOI":"10.1128\/JVI.00500-16","volume":"90","author":"D Anghelina","year":"2016","unstructured":"Anghelina, D., Lam, E., & Falck-Pedersen, E. (2016). Diminished innate antiviral response to adenovirus vectors in cGAS\/STING-deficient mice minimally impacts adaptive immunity. Journal of Virology, 90, 5915\u20135927.","journal-title":"Journal of Virology"},{"key":"159_CR11","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1159\/000207194","volume":"1","author":"DM Appledorn","year":"2009","unstructured":"Appledorn, D. M., Patial, S., Godbehere, S., Parameswaran, N., & Amalfitano, A. (2009). TRIF, and TRIF-interacting TLRs differentially modulate several adenovirus vector-induced immune responses. Journal of Innate Immunity, 1, 376\u2013388.","journal-title":"Journal of Innate Immunity"},{"key":"159_CR12","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.4049\/jimmunol.181.3.2134","volume":"181","author":"DM Appledorn","year":"2008","unstructured":"Appledorn, D. M., Patial, S., McBride, A., Godbehere, S., Van Rooijen, N., Parameswaran, N., & Amalfitano, A. (2008). Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo. The Journal of Immunology, 181, 2134\u20132144.","journal-title":"The Journal of Immunology"},{"key":"159_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.895713","volume":"10","author":"M Asmamaw Mengstie","year":"2022","unstructured":"Asmamaw Mengstie, M. (2022). Viral vectors for the in vivo delivery of CRISPR components: Advances and challenges. Frontiers in Bioengineering and Biotechnology, 10, 895713.","journal-title":"Frontiers in Bioengineering and Biotechnology"},{"key":"159_CR14","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3390\/v14050888","volume":"14","author":"S Atasheva","year":"2022","unstructured":"Atasheva, S., & Shayakhmetov, D. M. (2022). Cytokine responses to adenovirus and adenovirus vectors. Viruses, 14, 888.","journal-title":"Viruses"},{"key":"159_CR15","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.vaccine.2005.08.101","volume":"24","author":"DS Bangari","year":"2006","unstructured":"Bangari, D. S., & Mittal, S. K. (2006). Development of nonhuman adenoviruses as vaccine vectors. Vaccine, 24, 849\u2013862.","journal-title":"Vaccine"},{"key":"159_CR16","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","volume":"116","author":"DP Bartel","year":"2004","unstructured":"Bartel, D. P. (2004). MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell, 116, 281\u2013297.","journal-title":"Cell"},{"key":"159_CR17","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.3390\/v15051086","volume":"15","author":"EA Bates","year":"2023","unstructured":"Bates, E. A., Lovatt, C., Plein, A. R., Davies, J. A., Siebzehnrubl, F. A., & Parker, A. L. (2023). Engineering adenoviral vectors with improved GBM selectivity. Viruses, 15, 1086.","journal-title":"Viruses"},{"key":"159_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.607977","volume":"11","author":"EMS Beijnen","year":"2020","unstructured":"Beijnen, E. M. S., & van Haren, S. D. (2020). Vaccine-induced CD8+ T cell responses in children: A review of age-specific molecular determinants contributing to antigen cross-presentation. Frontiers in Immunology, 11, 607977.","journal-title":"Frontiers in Immunology"},{"key":"159_CR19","doi-asserted-by":"publisher","first-page":"7673","DOI":"10.1038\/sj.onc.1209040","volume":"24","author":"AJ Berk","year":"2005","unstructured":"Berk, A. J. (2005). Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene, 24, 7673\u20137685.","journal-title":"Oncogene"},{"key":"159_CR20","first-page":"616","volume":"6","author":"KL Berkner","year":"1988","unstructured":"Berkner, K. L. (1988). Development of adenovirus vectors for the expression of heterologous genes. BioTechniques, 6, 616\u2013629.","journal-title":"BioTechniques"},{"key":"159_CR21","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.omto.2021.11.014","volume":"23","author":"GWG Biegert","year":"2021","unstructured":"Biegert, G. W. G., Rosewell Shaw, A., & Suzuki, M. (2021). Current development in adenoviral vectors for cancer immunotherapy. Molecular Therapy Oncology, 23, 571\u2013581.","journal-title":"Molecular Therapy Oncology"},{"key":"159_CR22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nmeth854","volume":"3","author":"A Birmingham","year":"2006","unstructured":"Birmingham, A., Anderson, E. M., Reynolds, A., Ilsley-Tyree, D., Leake, D., Fedorov, Y., Baskerville, S., Maksimova, E., Robinson, K., Karpilow, J., et al. (2006). 3\u2032 UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nature Methods, 3, 199\u2013204.","journal-title":"Nature Methods"},{"key":"159_CR23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1126\/science.274.5286.373","volume":"274","author":"JR Bischoff","year":"1996","unstructured":"Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., & McCormick, F. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science, 274, 373\u2013376.","journal-title":"Science"},{"key":"159_CR24","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.1128\/JVI.02417-08","volume":"83","author":"AN Blackford","year":"2009","unstructured":"Blackford, A. N., & Grand, R. J. (2009). Adenovirus E1B 55-kilodalton protein: Multiple roles in viral infection and cell transformation. Journal of Virology, 83, 4000\u20134012.","journal-title":"Journal of Virology"},{"key":"159_CR25","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1089\/hum.2021.216","volume":"33","author":"STF Bots","year":"2022","unstructured":"Bots, S. T. F., Kemp, V., Cramer, S. J., van den Wollenberg, D. J. M., Hornsveld, M., Lamfers, M. L. M., van der Pluijm, G., & Hoeben, R. C. (2022). Nonhuman primate adenoviruses of the human adenovirus B species are potent and broadly acting oncolytic vector candidates. Human Gene Therapy, 33, 275\u2013289.","journal-title":"Human Gene Therapy"},{"key":"159_CR26","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1128\/JVI.06254-11","volume":"86","author":"RR Bradley","year":"2012","unstructured":"Bradley, R. R., Lynch, D. M., Iampietro, M. J., Borducchi, E. N., & Barouch, D. H. (2012). Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection. Journal of Virology, 86, 625\u2013629.","journal-title":"Journal of Virology"},{"key":"159_CR27","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.201800267","volume":"2","author":"E Brunner","year":"2019","unstructured":"Brunner, E., Yagi, R., Debrunner, M., Beck-Schneider, D., Burger, A., Escher, E., Mosimann, C., Hausmann, G., & Basler, K. (2019). CRISPR-induced double-strand breaks trigger recombination between homologous chromosome arms. Life Science Alliance, 2, e201800267.","journal-title":"Life Science Alliance"},{"key":"159_CR28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","volume":"6","author":"JT Bulcha","year":"2021","unstructured":"Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., & Gao, G. (2021). Viral vector platforms within the gene therapy landscape. Signal Transduction and Targeted Therapy, 6, 53.","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"159_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1023\/A:1008135928310","volume":"21","author":"HG Burgert","year":"2000","unstructured":"Burgert, H. G., & Blusch, J. H. (2000). Immunomodulatory functions encoded by the E3 transcription unit of adenoviruses. Virus Genes, 21, 13\u201325.","journal-title":"Virus Genes"},{"key":"159_CR30","doi-asserted-by":"publisher","first-page":"6400","DOI":"10.1128\/JVI.79.10.6400-6409.2005","volume":"79","author":"D Catalucci","year":"2005","unstructured":"Catalucci, D., Sporeno, E., Cirillo, A., Ciliberto, G., Nicosia, A., & Colloca, S. (2005). An adenovirus type 5 (Ad5) amplicon-based packaging cell line for production of high-capacity helper-independent \u0394E1-E2-E3-E4 Ad5 vectors. Journal of Virology, 79, 6400\u20136409.","journal-title":"Journal of Virology"},{"key":"159_CR31","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1002\/1873-3468.13695","volume":"593","author":"M Charman","year":"2019","unstructured":"Charman, M., Herrmann, C., & Weitzman, M. D. (2019). Viral and cellular interactions during adenovirus DNA replication. FEBS Letters, 593, 3531\u20133550.","journal-title":"FEBS Letters"},{"key":"159_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.615089","volume":"12","author":"D Chen","year":"2021","unstructured":"Chen, D., Huang, L., Zhou, H., & Zhang, Y. (2021). Combining IL-10 and oncolytic adenovirus demonstrates enhanced antitumor efficacy through CD8+ T cells. Frontiers in Immunology, 12, 615089.","journal-title":"Frontiers in Immunology"},{"key":"159_CR33","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/iub.1625","volume":"69","author":"N Chen","year":"2017","unstructured":"Chen, N., Xia, P., Li, S., Zhang, T., Wang, T. T., & Zhu, J. (2017). RNA sensors of the innate immune system and their detection of pathogens. IUBMB Life, 69, 297\u2013304.","journal-title":"IUBMB Life"},{"key":"159_CR34","first-page":"1968","volume":"12","author":"P Chen","year":"2019","unstructured":"Chen, P., Zhang, S. D., Lin, Y., Cao, J., Chen, J., & Yang, B. B. (2019). The construction and characterization of a novel adenovirus vector of artificial microRNA targeting EGFR. International Journal of Clinical and Experimental Pathology, 12, 1968\u20131974.","journal-title":"International Journal of Clinical and Experimental Pathology"},{"key":"159_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.685218","volume":"12","author":"C Ch\u00e9neau","year":"2021","unstructured":"Ch\u00e9neau, C., Eichholz, K., Tran, T. H., Tran, T. T. P., Paris, O., Henriquet, C., Bajramovic, J. J., Pugniere, M., & Kremer, E. J. (2021). Lactoferrin retargets human adenoviruses to TLR4 to induce an abortive NLRP3-associated pyroptotic response in human phagocytes. Frontiers in Immunology, 12, 685218.","journal-title":"Frontiers in Immunology"},{"key":"159_CR36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/978-1-61779-095-9_5","volume":"737","author":"M Chillon","year":"2011","unstructured":"Chillon, M., & Alemany, R. (2011). Methods to construct recombinant adenovirus vectors. Methods in Molecular Biology, 737, 117\u2013138.","journal-title":"Methods in Molecular Biology"},{"key":"159_CR37","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1089\/hum.2014.016","volume":"25","author":"L Coughlan","year":"2014","unstructured":"Coughlan, L., Uusi-Kerttula, H., Ma, J., Degg, B. P., Parker, A. L., & Baker, A. H. (2014). Retargeting adenovirus serotype 48 fiber knob domain by peptide incorporation. Human Gene Therapy, 25, 385\u2013394.","journal-title":"Human Gene Therapy"},{"key":"159_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0202820","volume":"13","author":"F Cox","year":"2018","unstructured":"Cox, F., van der Fits, L., Abbink, P., Larocca, R. A., van Huizen, E., Saeland, E., Verhagen, J., Peterson, R., Tolboom, J., Kaufmann, B., et al. (2018). Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge. PLoS\u00a0One, 13, e0202820.","journal-title":"PLoS\u00a0One"},{"key":"159_CR39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3390\/genes8020079","volume":"8","author":"CM Crosby","year":"2017","unstructured":"Crosby, C. M., & Barry, M. A. (2017). Transgene expression and host cell responses to replication-defective, single-cycle, and replication-competent adenovirus vectors. Genes, 8, 79.","journal-title":"Genes"},{"key":"159_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/hum.2013.2527","volume":"25","author":"RG Crystal","year":"2014","unstructured":"Crystal, R. G. (2014). Adenovirus: The first effective in vivo gene delivery vector. Human Gene Therapy, 25, 3\u201311.","journal-title":"Human Gene Therapy"},{"key":"159_CR41","doi-asserted-by":"publisher","first-page":"4547","DOI":"10.1128\/JVI.76.9.4547-4558.2002","volume":"76","author":"A Cuconati","year":"2002","unstructured":"Cuconati, A., Degenhardt, K., Sundararajan, R., Anschel, A., & White, E. (2002). Bak and bax function to limit adenovirus replication through apoptosis induction. Journal of Virology, 76, 4547\u20134558.","journal-title":"Journal of Virology"},{"key":"159_CR42","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.cellimm.2006.08.006","volume":"242","author":"CS Curran","year":"2006","unstructured":"Curran, C. S., Demick, K. P., & Mansfield, J. M. (2006). Lactoferrin activates macrophages via TLR4-dependent and -independent signaling pathways. Cellular Immunology, 242, 23\u201330.","journal-title":"Cellular Immunology"},{"key":"159_CR43","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.cvsm.2008.02.006","volume":"38","author":"N Decaro","year":"2008","unstructured":"Decaro, N., Martella, V., & Buonavoglia, C. (2008). Canine adenoviruses and herpesvirus. Veterinary Clinics of North America: Small Animal Practice, 38, 799\u2013814.","journal-title":"Veterinary Clinics of North America: Small Animal Practice"},{"key":"159_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040385","volume":"7","author":"MD Dicks","year":"2012","unstructured":"Dicks, M. D., Spencer, A. J., Edwards, N. J., Wadell, G., Bojang, K., Gilbert, S. C., Hill, A. V., & Cottingham, M. G. (2012). A novel chimpanzee adenovirus vector with low human seroprevalence: Improved systems for vector derivation and comparative immunogenicity. PLoS\u00a0One, 7, e40385.","journal-title":"PLoS\u00a0One"},{"key":"159_CR45","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1158\/1535-7163.MCT-21-0240","volume":"21","author":"J Doerner","year":"2022","unstructured":"Doerner, J., Sallard, E., Zhang, W., Solanki, M., Liu, J., Ehrke-Schulz, E., Zirngibl, H., Lieber, A., & Ehrhardt, A. (2022). Novel group C oncolytic adenoviruses carrying a miRNA inhibitor demonstrate enhanced oncolytic activity in vitro and in vivo. Molecular Cancer Therapeutics, 21, 460\u2013470.","journal-title":"Molecular Cancer Therapeutics"},{"key":"159_CR46","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2174\/18715206113139990309","volume":"14","author":"JC Doloff","year":"2014","unstructured":"Doloff, J. C., & Waxman, D. J. (2014). Adenoviral vectors for prodrug activation-based gene therapy for cancer. Anti-Cancer Agents in Medicinal Chemistry, 14, 115\u2013126.","journal-title":"Anti-Cancer Agents in Medicinal Chemistry"},{"key":"159_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24729","volume":"36","author":"F Dong","year":"2022","unstructured":"Dong, F., Su, L., Tan, J., & Luo, H. (2022). The anticancer effect of EGFR-targeting artificial microRNA controlled by SLPI promoter in nasopharyngeal carcinoma. Journal of Clinical Laboratory Analysis, 36, e24729.","journal-title":"Journal of Clinical Laboratory Analysis"},{"key":"159_CR48","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1089\/hum.1996.7.17-2101","volume":"7","author":"JY Dong","year":"1996","unstructured":"Dong, J. Y., Fan, P. D., & Frizzell, R. A. (1996). Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Human Gene Therapy, 7, 2101\u20132112.","journal-title":"Human Gene Therapy"},{"key":"159_CR49","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nrmicro2240","volume":"8","author":"SJ Draper","year":"2010","unstructured":"Draper, S. J., & Heeney, J. L. (2010). Viruses as vaccine vectors for infectious diseases and cancer. Nature Reviews Microbiology, 8, 62\u201373.","journal-title":"Nature Reviews Microbiology"},{"key":"159_CR50","doi-asserted-by":"publisher","DOI":"10.6064\/2012\/694137","volume":"2012","author":"I Dufait","year":"2012","unstructured":"Dufait, I., Liechtenstein, T., Lanna, A., Bricogne, C., Laranga, R., Padella, A., Breckpot, K., & Escors, D. (2012). Retroviral and lentiviral vectors for the induction of immunological tolerance. Scientifica, 2012, 694137.","journal-title":"Scientifica"},{"key":"159_CR51","doi-asserted-by":"publisher","first-page":"5437","DOI":"10.1128\/JVI.79.9.5437-5444.2005","volume":"79","author":"GJ Duigou","year":"2005","unstructured":"Duigou, G. J., & Young, C. S. (2005). Replication-competent adenovirus formation in 293 cells: The recombination-based rate is influenced by structure and location of the transgene cassette and not increased by overproduction of HsRad51, Rad51-interacting, or E2F family proteins. Journal of Virology, 79, 5437\u20135444.","journal-title":"Journal of Virology"},{"key":"159_CR52","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1128\/CMR.00052-07","volume":"21","author":"M Echavarr\u00eda","year":"2008","unstructured":"Echavarr\u00eda, M. (2008). Adenoviruses in immunocompromised hosts. Clinical Microbiology Reviews, 21, 704\u2013715.","journal-title":"Clinical Microbiology Reviews"},{"key":"159_CR53","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.3390\/cancers12071934","volume":"12","author":"E Ehrke-Schulz","year":"2020","unstructured":"Ehrke-Schulz, E., Heinemann, S., Schulte, L., Schiwon, M., & Ehrhardt, A. (2020). Adenoviral vectors armed with PAPILLOMAVIRUs oncogene specific CRISPR\/Cas9 kill human-papillomavirus-induced cervical cancer cells. Cancers, 12, 1934.","journal-title":"Cancers"},{"key":"159_CR54","doi-asserted-by":"publisher","first-page":"17113","DOI":"10.1038\/s41598-017-17180-w","volume":"7","author":"E Ehrke-Schulz","year":"2017","unstructured":"Ehrke-Schulz, E., Schiwon, M., Leitner, T., D\u00e1vid, S., Bergmann, T., Liu, J., & Ehrhardt, A. (2017). CRISPR\/Cas9 delivery with one single adenoviral vector devoid of all viral genes. Scientific Reports, 7, 17113.","journal-title":"Scientific Reports"},{"key":"159_CR55","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrc1840","volume":"6","author":"A Esquela-Kerscher","year":"2006","unstructured":"Esquela-Kerscher, A., & Slack, F. J. (2006). Oncomirs\u2014microRNAs with a role in cancer. Nature Reviews Cancer, 6, 259\u2013269.","journal-title":"Nature Reviews Cancer"},{"key":"159_CR56","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1089\/hum.1998.9.13-1909","volume":"9","author":"FJ Fallaux","year":"1998","unstructured":"Fallaux, F. J., Bout, A., van der Velde, I., van den Wollenberg, D. J., Hehir, K. M., Keegan, J., Auger, C., Cramer, S. J., van Ormondt, H., van der Eb, A. J., et al. (1998). New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Human Gene Therapy, 9, 1909\u20131917.","journal-title":"Human Gene Therapy"},{"key":"159_CR57","doi-asserted-by":"publisher","first-page":"5630","DOI":"10.1128\/JVI.03518-13","volume":"88","author":"GJ Fonseca","year":"2014","unstructured":"Fonseca, G. J., Cohen, M. J., & Mymryk, J. S. (2014). Adenovirus E1A recruits the human Paf1 complex to enhance transcriptional elongation. Journal of Virology, 88, 5630\u20135637.","journal-title":"Journal of Virology"},{"key":"159_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0293046","volume":"18","author":"AG Francisco","year":"2023","unstructured":"Francisco, A. G., Reyes, J. C. B., Tabios, I. K. B., Cruz, C. J. G., Ang, M. A. C., Heralde, F. M., 3rd., Lacuna, A. R. G., & de Paz-Silava, S. L. M. (2023). Seroprevalence of human adenovirus type 5 neutralizing antibodies in the Philippines. PLoS\u00a0One, 18, e0293046.","journal-title":"PLoS\u00a0One"},{"key":"159_CR59","doi-asserted-by":"publisher","first-page":"42127","DOI":"10.1038\/srep42127","volume":"7","author":"H Gong","year":"2017","unstructured":"Gong, H., Liu, M., Klomp, J., Merrill, B. J., Rehman, J., & Malik, A. B. (2017). Method for dual viral vector mediated CRISPR-Cas9 gene disruption in primary human endothelial cells. Scientific Reports, 7, 42127.","journal-title":"Scientific Reports"},{"key":"159_CR60","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1099\/0022-1317-36-1-59","volume":"36","author":"FL Graham","year":"1977","unstructured":"Graham, F. L., Smiley, J., Russell, W. C., & Nairn, R. (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. The Journal of General Virology, 36, 59\u201374.","journal-title":"The Journal of General Virology"},{"key":"159_CR61","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.gde.2009.11.004","volume":"20","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov, S. I., & Karin, M. (2010). Inflammation and oncogenesis: A vicious connection. Current Opinion in Genetics & Development, 20, 65\u201371.","journal-title":"Current Opinion in Genetics & Development"},{"key":"159_CR62","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41586-023-06373-1","volume":"620","author":"MF Gulen","year":"2023","unstructured":"Gulen, M. F., Samson, N., Keller, A., Schwabenland, M., Liu, C., Gl\u00fcck, S., Thacker, V. V., Favre, L., Mangeat, B., Kroese, L. J., et al. (2023). cGAS-STING drives ageing-related inflammation and neurodegeneration. Nature, 620, 374\u2013380.","journal-title":"Nature"},{"key":"159_CR63","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/0022-2836(84)90154-2","volume":"178","author":"DL Hamilton","year":"1984","unstructured":"Hamilton, D. L., & Abremski, K. (1984). Site-specific recombination by the bacteriophage P1 lox-cre system. Cre-mediated synapsis of two lox sites. Journal of Molecular Biology, 178, 481\u2013486.","journal-title":"Journal of Molecular Biology"},{"key":"159_CR64","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1128\/CVI.00144-09","volume":"16","author":"C Harro","year":"2009","unstructured":"Harro, C., Sun, X., Stek, J. E., Leavitt, R. Y., Mehrotra, D. V., Wang, F., Bett, A. J., Casimiro, D. R., Shiver, J. W., DiNubile, M. J., et al. (2009). Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults. Clinical and Vaccine Immunology, 16, 1285\u20131292.","journal-title":"Clinical and Vaccine Immunology"},{"key":"159_CR65","doi-asserted-by":"publisher","first-page":"4612","DOI":"10.1128\/JVI.76.9.4612-4620.2002","volume":"76","author":"MJ Havenga","year":"2002","unstructured":"Havenga, M. J., Lemckert, A. A., Ophorst, O. J., van Meijer, M., Germeraad, W. T., Grimbergen, J., van Den Doel, M. A., Vogels, R., van Deutekom, J., Janson, A. A., et al. (2002). Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. Journal of Virology, 76, 4612\u20134620.","journal-title":"Journal of Virology"},{"key":"159_CR66","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nature03552","volume":"435","author":"L He","year":"2005","unstructured":"He, L., Thomson, J. M., Hemann, M. T., Hernando-Monge, E., Mu, D., Goodson, S., Powers, S., Cordon-Cardo, C., Lowe, S. W., Hannon, G. J., et al. (2005). A microRNA polycistron as a potential human oncogene. Nature, 435, 828\u2013833.","journal-title":"Nature"},{"key":"159_CR67","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1073\/pnas.95.5.2509","volume":"95","author":"TC He","year":"1998","unstructured":"He, T. C., Zhou, S., da Costa, L. T., Yu, J., Kinzler, K. W., & Vogelstein, B. (1998). A simplified system for generating recombinant adenoviruses. Proceedings of the National Academy of Sciences, 95, 2509\u20132514.","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"159_CR68","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.3389\/fimmu.2017.01456","volume":"8","author":"M Hemmi","year":"2017","unstructured":"Hemmi, M., Tachibana, M., Fujimoto, N., Shoji, M., Sakurai, F., Kobiyama, K., Ishii, K. J., Akira, S., & Mizuguchi, H. (2017). T helper 17 promotes induction of antigen-specific gut-mucosal cytotoxic T lymphocytes following adenovirus vector vaccination. Frontiers in Immunology, 8, 1456.","journal-title":"Frontiers in Immunology"},{"key":"159_CR69","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1038\/mt.2012.115","volume":"20","author":"O Hemminki","year":"2012","unstructured":"Hemminki, O., Diaconu, I., Cerullo, V., Pesonen, S. K., Kanerva, A., Joensuu, T., Kairemo, K., Laasonen, L., Partanen, K., Kangasniemi, L., et al. (2012). Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer. Molecular Therapy, 20, 1821\u20131830.","journal-title":"Molecular Therapy"},{"key":"159_CR70","doi-asserted-by":"publisher","first-page":"7283","DOI":"10.1016\/j.vaccine.2015.10.111","volume":"33","author":"S Herath","year":"2015","unstructured":"Herath, S., Le Heron, A., Colloca, S., Bergin, P., Patterson, S., Weber, J., Tatoud, R., & Dickson, G. (2015). Analysis of T cell responses to chimpanzee adenovirus vectors encoding HIV gag-pol-nef antigen. Vaccine, 33, 7283\u20137289.","journal-title":"Vaccine"},{"key":"159_CR71","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1126\/science.1164206","volume":"322","author":"K Hildner","year":"2008","unstructured":"Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., et al. (2008). Batf3 deficiency reveals a critical role for CD8\u03b1+ dendritic cells in cytotoxic T cell immunity. Science, 322, 1097\u20131100.","journal-title":"Science"},{"key":"159_CR72","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3181\/00379727-85-20825","volume":"85","author":"MR Hilleman","year":"1954","unstructured":"Hilleman, M. R., & Werner, J. H. (1954). Recovery of new agent from patients with acute respiratory illness. Proceedings of the Society for Experimental Biology and Medicine, 85, 183\u2013188.","journal-title":"Proceedings of the Society for Experimental Biology and Medicine"},{"key":"159_CR73","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1073\/pnas.94.6.2587","volume":"94","author":"Y Ilan","year":"1997","unstructured":"Ilan, Y., Droguett, G., Chowdhury, N. R., Li, Y., Sengupta, K., Thummala, N. R., Davidson, A., Chowdhury, J. R., & Horwitz, M. S. (1997). Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proceedings of the National Academy of Sciences of the United States of America, 94, 2587\u20132592.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"159_CR74","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.DMIH2-0020-2015","author":"MG Ison","year":"2016","unstructured":"Ison, M. G., & Hayden, R. T. (2016). Adenovirus. Microbiology Spectrum. https:\/\/doi.org\/10.1128\/microbiolspec.DMIH2-0020-2015","journal-title":"Microbiology Spectrum"},{"key":"159_CR75","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1126\/science.1183021","volume":"327","author":"A Iwasaki","year":"2010","unstructured":"Iwasaki, A., & Medzhitov, R. (2010). Regulation of adaptive immunity by the innate immune system. Science, 327, 291\u2013295.","journal-title":"Science"},{"key":"159_CR76","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1073\/pnas.69.10.2904","volume":"69","author":"DA Jackson","year":"1972","unstructured":"Jackson, D. A., Symons, R. H., & Berg, P. (1972). Biochemical method for inserting new genetic information into DNA of simian virus 40: Circular SV40 DNA molecules containing lambda phage genes and the galactose operon of Escherichia coli. Proceedings of the National Academy of Sciences of the United States of America, 69, 2904\u20132909.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"159_CR77","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41598-018-36736-y","volume":"9","author":"YH Jin","year":"2019","unstructured":"Jin, Y. H., Joo, H., Lee, K., Kim, H., Didier, R., Yang, Y., Shin, H., & Lee, C. (2019). Streamlined procedure for gene knockouts using all-in-one adenoviral CRISPR-Cas9. Scientific Reports, 9, 277.","journal-title":"Scientific Reports"},{"key":"159_CR78","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S0140-6736(21)00191-4","volume":"397","author":"I Jones","year":"2021","unstructured":"Jones, I., & Roy, P. (2021). Sputnik V COVID-19 vaccine candidate appears safe and effective. Lancet, 397, 642\u2013643.","journal-title":"Lancet"},{"key":"159_CR79","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S1525-0016(03)00200-4","volume":"8","author":"A Kanerva","year":"2003","unstructured":"Kanerva, A., Zinn, K. R., Chaudhuri, T. R., Lam, J. T., Suzuki, K., Uil, T. G., Hakkarainen, T., Bauerschmitz, G. J., Wang, M., Liu, B., et al. (2003). Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Molecular Therapy, 8, 449\u2013458.","journal-title":"Molecular Therapy"},{"key":"159_CR80","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3389\/fimmu.2014.00461","volume":"5","author":"T Kawasaki","year":"2014","unstructured":"Kawasaki, T., & Kawai, T. (2014). Toll-like receptor signaling pathways. Frontiers in Immunology, 5, 461.","journal-title":"Frontiers in Immunology"},{"key":"159_CR81","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41541-022-00567-w","volume":"7","author":"S Khan","year":"2022","unstructured":"Khan, S., Salisch, N. C., Gil, A. I., Boedhoe, S., Boer, K. F., Serroyen, J., Schuitemaker, H., & Zahn, R. C. (2022). Sequential use of AD26-based vaccine regimens in NHP to induce immunity against different disease targets. Npj Vaccines, 7, 146.","journal-title":"Npj Vaccines"},{"key":"159_CR82","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1089\/hum.1997.8.17-2103","volume":"8","author":"B Klonjkowski","year":"1997","unstructured":"Klonjkowski, B., Gilardi-Hebenstreit, P., Hadchouel, J., Randrianarison, V., Boutin, S., Yeh, P., Perricaudet, M., & Kremer, E. J. (1997). A recombinant E1-deleted canine adenoviral vector capable of transduction and expression of a transgene in human-derived cells and in vivo. Human Gene Therapy, 8, 2103\u20132115.","journal-title":"Human Gene Therapy"},{"key":"159_CR83","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.3390\/v2081681","volume":"2","author":"I Kovesdi","year":"2010","unstructured":"Kovesdi, I., & Hedley, S. J. (2010). Adenoviral producer cells. Viruses, 2, 1681\u20131703.","journal-title":"Viruses"},{"key":"159_CR84","doi-asserted-by":"publisher","first-page":"14426","DOI":"10.1128\/JVI.02608-14","volume":"88","author":"E Lam","year":"2014","unstructured":"Lam, E., & Falck-Pedersen, E. (2014). Unabated adenovirus replication following activation of the cGAS\/STING-dependent antiviral response in human cells. Journal of Virology, 88, 14426\u201314439.","journal-title":"Journal of Virology"},{"key":"159_CR85","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3390\/vaccines11010148","volume":"11","author":"C Lamb","year":"2023","unstructured":"Lamb, C., Owens, C., Gamboa, W., & Lopez-Yunez, A. (2023). Evaluating Johnson and Johnson COVID-19 vaccination outcomes in a low-income hispanic population. Vaccines, 11, 148.","journal-title":"Vaccines"},{"key":"159_CR86","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/mt.2009.130","volume":"17","author":"MO Lasaro","year":"2009","unstructured":"Lasaro, M. O., & Ertl, H. C. (2009). New insights on adenovirus as vaccine vectors. Molecular Therapy, 17, 1333\u20131339.","journal-title":"Molecular Therapy"},{"key":"159_CR87","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1016\/S0140-6736(21)02329-1","volume":"398","author":"R Lazarus","year":"2021","unstructured":"Lazarus, R., Baos, S., Cappel-Porter, H., Carson-Stevens, A., Clout, M., Culliford, L., Emmett, S. R., Garstang, J., Gbadamoshi, L., Hallis, B., et al. (2021). Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): A multicentre, randomised, controlled, phase 4 trial. Lancet, 398, 2277\u20132287.","journal-title":"Lancet"},{"key":"159_CR88","doi-asserted-by":"publisher","first-page":"9694","DOI":"10.1128\/JVI.79.15.9694-9701.2005","volume":"79","author":"AA Lemckert","year":"2005","unstructured":"Lemckert, A. A., Sumida, S. M., Holterman, L., Vogels, R., Truitt, D. M., Lynch, D. M., Nanda, A., Ewald, B. A., Gorgone, D. A., Lifton, M. A., et al. (2005). Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. Journal of Virology, 79, 9694\u20139701.","journal-title":"Journal of Virology"},{"key":"159_CR89","doi-asserted-by":"publisher","first-page":"5844","DOI":"10.1073\/pnas.83.16.5844","volume":"83","author":"K Leong","year":"1986","unstructured":"Leong, K., & Berk, A. J. (1986). Adenovirus early region 1A protein increases the number of template molecules transcribed in cell-free extracts. Proceedings of the National Academy of Sciences of the United States of America, 83, 5844\u20135848.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"159_CR90","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/0092-8674(80)90138-5","volume":"21","author":"JB Lewis","year":"1980","unstructured":"Lewis, J. B., & Mathews, M. B. (1980). Control of adenovirus early gene expression: A class of immediate early products. Cell, 21, 303\u2013313.","journal-title":"Cell"},{"key":"159_CR91","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1099\/vir.0.000139","volume":"96","author":"C Li","year":"2015","unstructured":"Li, C., Guan, X., Du, T., Jin, W., Wu, B., Liu, Y., Wang, P., Hu, B., Griffin, G. E., Shattock, R. J., et al. (2015). Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR\/Cas9. The Journal of General Virology, 96, 2381\u20132393.","journal-title":"The Journal of General Virology"},{"key":"159_CR92","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/imm.12957","volume":"155","author":"R Li","year":"2018","unstructured":"Li, R., Liu, J., Wu, S., Zai, X., Li, Y., Yang, Q., Hou, L., Xu, J., & Chen, W. (2018). Toll-like receptor 4 signalling regulates antibody response to adenoviral vector-based vaccines by imprinting germinal centre quality. Immunology, 155, 251\u2013262.","journal-title":"Immunology"},{"key":"159_CR93","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2174\/1568009618666171129221503","volume":"18","author":"M Liang","year":"2018","unstructured":"Liang, M. (2018). Oncorine, the world first oncolytic virus medicine and its update in China. Current Cancer Drug Targets, 18, 171\u2013176.","journal-title":"Current Cancer Drug Targets"},{"key":"159_CR94","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/08830180490265556","volume":"23","author":"DL Lichtenstein","year":"2004","unstructured":"Lichtenstein, D. L., Toth, K., Doronin, K., Tollefson, A. E., & Wold, W. S. (2004). Functions and mechanisms of action of the adenovirus E3 proteins. International Reviews of Immunology, 23, 75\u2013111.","journal-title":"International Reviews of Immunology"},{"key":"159_CR95","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","volume":"8","author":"D Lin","year":"2023","unstructured":"Lin, D., Shen, Y., & Liang, T. (2023). Oncolytic virotherapy: Basic principles, recent advances and future directions. Signal Transduction and Targeted Therapy, 8, 156.","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"159_CR96","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.4049\/jimmunol.179.3.1721","volume":"179","author":"K Lor\u00e9","year":"2007","unstructured":"Lor\u00e9, K., Adams, W. C., Havenga, M., Precopio, M. L., Holterman, L., Goudsmit, J., & Koup, R. A. (2007). Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses. The Journal of Immunology, 179, 1721\u20131729.","journal-title":"The Journal of Immunology"},{"key":"159_CR97","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1055\/s-0031-1283287","volume":"32","author":"JP Lynch","year":"2011","unstructured":"Lynch, J. P., Fishbein, M., & Echavarria, M. (2011). Adenovirus. Seminars in Respiratory and Critical Care Medicine, 32, 494\u2013511.","journal-title":"Seminars in Respiratory and Critical Care Medicine"},{"key":"159_CR98","doi-asserted-by":"publisher","first-page":"159","DOI":"10.15586\/aei.v51i1.737","volume":"51","author":"JP Ma","year":"2023","unstructured":"Ma, J. P., Yao, C. Z., Jia, Z. Q., Wang, A. M., Miao, X. X., Gao, X. X., & Su, L. P. (2023). TRIM52 aggravated inflammation and pyroptosis in dextran sulfate sodium-induced inflammatory bowel disease through activation of the TLR4\/NF-\u03baBs pathway. Allergologia Et Immunopathologia, 51, 159\u2013167.","journal-title":"Allergologia Et Immunopathologia"},{"key":"159_CR99","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nature23449","volume":"548","author":"KJ Mackenzie","year":"2017","unstructured":"Mackenzie, K. J., Carroll, P., Martin, C. A., Murina, O., Fluteau, A., Simpson, D. J., Olova, N., Sutcliffe, H., Rainger, J. K., Leitch, A., et al. (2017). cGAS surveillance of micronuclei links genome instability to innate immunity. Nature, 548, 461\u2013465.","journal-title":"Nature"},{"key":"159_CR100","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3390\/vaccines11020268","volume":"11","author":"S Malik","year":"2023","unstructured":"Malik, S., Kishore, S., Nag, S., Dhasmana, A., Preetam, S., Mitra, O., Le\u00f3n-Figueroa, D. A., Mohanty, A., Chattu, V. K., Assefi, M., et al. (2023). Ebola virus disease vaccines: Development, current perspectives & challenges. Vaccines, 11, 268.","journal-title":"Vaccines"},{"key":"159_CR101","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/d41586-021-00785-7","volume":"592","author":"S Mallapaty","year":"2021","unstructured":"Mallapaty, S., & Callaway, E. (2021). What scientists do and don\u2019t know about the Oxford-Astrazeneca COVID vaccine. Nature, 592, 15\u201317.","journal-title":"Nature"},{"key":"159_CR102","doi-asserted-by":"publisher","DOI":"10.1172\/JCI140794","volume":"131","author":"K Matsuda","year":"2021","unstructured":"Matsuda, K., Migueles, S. A., Huang, J., Bolkhovitinov, L., Stuccio, S., Griesman, T., Pullano, A. A., Kang, B. H., Ishida, E., Zimmerman, M., et al. (2021). A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity. The Journal of Clinical Investigation, 131, e140794.","journal-title":"The Journal of Clinical Investigation"},{"key":"159_CR103","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/nature06246","volume":"449","author":"R Medzhitov","year":"2007","unstructured":"Medzhitov, R. (2007). Recognition of microorganisms and activation of the immune response. Nature, 449, 819\u2013826.","journal-title":"Nature"},{"key":"159_CR104","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41541-021-00356-x","volume":"6","author":"SA Mendon\u00e7a","year":"2021","unstructured":"Mendon\u00e7a, S. A., Lorincz, R., Boucher, P., & Curiel, D. T. (2021). Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. Npj Vaccines, 6, 97.","journal-title":"Npj Vaccines"},{"key":"159_CR105","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1001\/jama.2016.4218","volume":"315","author":"ID Milligan","year":"2016","unstructured":"Milligan, I. D., Gibani, M. M., Sewell, R., Clutterbuck, E. A., Campbell, D., Plested, E., Nuthall, E., Voysey, M., Silva-Reyes, L., McElrath, M. J., et al. (2016). Safety and immunogenicity of novel adenovirus type 26\u2013 and modified vaccinia ankara\u2013vectored Ebola vaccines: A randomized clinical trial. JAMA, 315, 1610\u20131623.","journal-title":"JAMA"},{"key":"159_CR106","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1089\/hum.1998.9.17-2577","volume":"9","author":"H Mizuguchi","year":"1998","unstructured":"Mizuguchi, H., & Kay, M. A. (1998). Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Human Gene Therapy, 9, 2577\u20132583.","journal-title":"Human Gene Therapy"},{"key":"159_CR107","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0169-409X(01)00215-0","volume":"52","author":"H Mizuguchi","year":"2001","unstructured":"Mizuguchi, H., Kay, M. A., & Hayakawa, T. (2001). Approaches for generating recombinant adenovirus vectors. Advanced Drug Delivery Reviews, 52, 165\u2013176.","journal-title":"Advanced Drug Delivery Reviews"},{"key":"159_CR108","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/S1470-2045(24)00079-2","volume":"25","author":"BL Musher","year":"2024","unstructured":"Musher, B. L., Rowinsky, E. K., Smaglo, B. G., Abidi, W., Othman, M., Patel, K., Jawaid, S., Jing, J., Brisco, A., Leen, A. M., et al. (2024). LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): Results from arm 1 of a non-randomised, single-centre, phase 1\/2 study. Lancet Oncology, 25, 488\u2013500.","journal-title":"Lancet Oncology"},{"key":"159_CR109","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","volume":"31","author":"MF Naso","year":"2017","unstructured":"Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017). Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs, 31, 317\u2013334.","journal-title":"BioDrugs"},{"key":"159_CR110","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.omto.2021.11.011","volume":"23","author":"N Ni","year":"2021","unstructured":"Ni, N., Deng, F., He, F., Wang, H., Shi, D., Liao, J., Zou, Y., Wang, H., Zhao, P., Hu, X., et al. (2021). A one-step construction of adenovirus (OSCA) system using the Gibson DNA assembly technology. Molecular Therapy Oncolytics, 23, 602\u2013611.","journal-title":"Molecular Therapy Oncolytics"},{"key":"159_CR111","first-page":"351","volume":"11","author":"E Nwanegbo","year":"2004","unstructured":"Nwanegbo, E., Vardas, E., Gao, W., Whittle, H., Sun, H., Rowe, D., Robbins, P. D., & Gambotto, A. (2004). Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of the Gambia, South Africa, and the United States. Clinical and Diagnostic Laboratory Immunology, 11, 351\u2013357.","journal-title":"Clinical and Diagnostic Laboratory Immunology"},{"key":"159_CR112","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.745016","volume":"11","author":"GH Ong","year":"2021","unstructured":"Ong, G. H., Lian, B. S. X., Kawasaki, T., & Kawai, T. (2021). Exploration of pattern recognition receptor agonists as candidate adjuvants. Frontiers in Cellular and Infection Microbiology, 11, 745016.","journal-title":"Frontiers in Cellular and Infection Microbiology"},{"key":"159_CR113","doi-asserted-by":"publisher","first-page":"14464","DOI":"10.1038\/s41598-022-18750-3","volume":"12","author":"E Padron-Regalado","year":"2022","unstructured":"Padron-Regalado, E., Ulaszewska, M., Douglas, A. D., Hill, A. V. S., & Spencer, A. J. (2022). STING-pathway modulation to enhance the immunogenicity of adenoviral-vectored vaccines. Scientific Reports, 12, 14464.","journal-title":"Scientific Reports"},{"key":"159_CR114","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.3390\/cancers12113354","volume":"12","author":"M Peter","year":"2020","unstructured":"Peter, M., & K\u00fchnel, F. (2020). Oncolytic adenovirus in cancer immunotherapy. Cancers, 12, 3354.","journal-title":"Cancers"},{"key":"159_CR115","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.omtm.2021.12.001","volume":"24","author":"S Phillips","year":"2022","unstructured":"Phillips, S., Ramos, P. V., Veeraraghavan, P., & Young, S. M., Jr. (2022). VikAD, a Vika site-specific recombinase-based system for efficient and scalable helper-dependent adenovirus production. Molecular Therapy Methods & Clinical Development, 24, 117\u2013126.","journal-title":"Molecular Therapy Methods & Clinical Development"},{"key":"159_CR116","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.3390\/v13081526","volume":"13","author":"V Poletti","year":"2021","unstructured":"Poletti, V., & Mavilio, F. (2021). Designing lentiviral vectors for gene therapy of genetic diseases. Viruses, 13, 1526.","journal-title":"Viruses"},{"key":"159_CR117","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1126\/science.aax8819","volume":"371","author":"NM Provine","year":"2021","unstructured":"Provine, N. M., Amini, A., Garner, L. C., Spencer, A. J., Dold, C., Hutchings, C., Silva Reyes, L., FitzPatrick, M. E. B., Chinnakannan, S., Oguti, B., et al. (2021). MAIT cell activation augments adenovirus vector vaccine immunogenicity. Science, 371, 521\u2013526.","journal-title":"Science"},{"key":"159_CR118","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3390\/vaccines12020210","volume":"12","author":"A Puri","year":"2024","unstructured":"Puri, A., Pollard, A. J., Schmidt-Mutter, C., Lain\u00e9, F., PrayGod, G., Kibuuka, H., Barry, H., Nicolas, J. F., Leli\u00e8vre, J. D., Sirima, S. B., et al. (2024). Long-term clinical safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: a prospective, multi-country, observational study. Vaccines, 12, 210.","journal-title":"Vaccines"},{"key":"159_CR119","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/QCO.0000000000000451","volume":"31","author":"JR Radke","year":"2018","unstructured":"Radke, J. R., & Cook, J. L. (2018). Human adenovirus infections: Update and consideration of mechanisms of viral persistence. Current Opinion in Infectious Diseases, 31, 251\u2013256.","journal-title":"Current Opinion in Infectious Diseases"},{"key":"159_CR120","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.3390\/v13122505","volume":"13","author":"J Rajaiya","year":"2021","unstructured":"Rajaiya, J., Saha, A., Zhou, X., & Chodosh, J. (2021). Human adenovirus species D interactions with corneal stromal cells. Viruses, 13, 2505.","journal-title":"Viruses"},{"key":"159_CR121","doi-asserted-by":"publisher","first-page":"229","DOI":"10.4103\/0973-029X.140762","volume":"18","author":"K Ranganathan","year":"2014","unstructured":"Ranganathan, K., & Sivasankar, V. (2014). MicroRNAs\u2014biology and clinical applications. Journal of Oral and Maxillofacial Pathology, 18, 229\u2013234.","journal-title":"Journal of Oral and Maxillofacial Pathology"},{"key":"159_CR122","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41591-024-02851-9","volume":"30","author":"AR Rappaport","year":"2024","unstructured":"Rappaport, A. R., Kyi, C., Lane, M., Hart, M. G., Johnson, M. L., Henick, B. S., Liao, C. Y., Mahipal, A., Shergill, A., Spira, A. I., et al. (2024). A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: Phase 1 trial interim results. Nature Medicine, 30, 1013\u20131022.","journal-title":"Nature Medicine"},{"key":"159_CR123","doi-asserted-by":"publisher","first-page":"134","DOI":"10.2144\/99261rr02","volume":"26","author":"CK Raymond","year":"1999","unstructured":"Raymond, C. K., Pownder, T. A., & Sexson, S. L. (1999). General method for plasmid construction using homologous recombination. BioTechniques, 26, 134\u2013141.","journal-title":"BioTechniques"},{"key":"159_CR124","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1136\/archdischild-2016-310459","volume":"101","author":"M Redman","year":"2016","unstructured":"Redman, M., King, A., Watson, C., & King, D. (2016). What is CRISPR\/Cas9? Archives of Disease in Childhood Education and Practice, 101, 213\u2013215.","journal-title":"Archives of Disease in Childhood Education and Practice"},{"key":"159_CR125","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41577-020-0288-3","volume":"20","author":"J Rehwinkel","year":"2020","unstructured":"Rehwinkel, J., & Gack, M. U. (2020). RIG-I-Like receptors: Their regulation and roles in RNA sensing. Nature Reviews Immunology, 20, 537\u2013551.","journal-title":"Nature Reviews Immunology"},{"key":"159_CR126","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/sj.cgt.7700539","volume":"9","author":"T Reid","year":"2002","unstructured":"Reid, T., Warren, R., & Kirn, D. (2002). Intravascular adenoviral agents in cancer patients: Lessons from clinical trials. Cancer Gene Therapy, 9, 979\u2013986.","journal-title":"Cancer Gene Therapy"},{"key":"159_CR127","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.3390\/ijms21103643","volume":"21","author":"A Ricobaraza","year":"2020","unstructured":"Ricobaraza, A., Gonzalez-Aparicio, M., Mora-Jimenez, L., Lumbreras, S., & Hernandez-Alcoceba, R. (2020). High-capacity adenoviral vectors: Expanding the scope of gene therapy. International Journal of Molecular Sciences, 21, 3643.","journal-title":"International Journal of Molecular Sciences"},{"key":"159_CR128","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nature04721","volume":"441","author":"DM Roberts","year":"2006","unstructured":"Roberts, D. M., Nanda, A., Havenga, M. J., Abbink, P., Lynch, D. M., Ewald, B. A., Liu, J., Thorner, A. R., Swanson, P. E., Gorgone, D. A., et al. (2006). Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature, 441, 239\u2013243.","journal-title":"Nature"},{"key":"159_CR129","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3181\/00379727-84-20714","volume":"84","author":"WP Rowe","year":"1953","unstructured":"Rowe, W. P., Huebner, R. J., Gilmore, L. K., Parrott, R. H., & Ward, T. G. (1953). Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proceedings of the Society for Experimental Biology and Medicine, 84, 570\u2013573.","journal-title":"Proceedings of the Society for Experimental Biology and Medicine"},{"key":"159_CR130","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/jgm.1530","volume":"13","author":"S Roy","year":"2011","unstructured":"Roy, S., Medina-Jaszek, A., Wilson, M. J., Sandhu, A., Calcedo, R., Lin, J., & Wilson, J. M. (2011). Creation of a panel of vectors based on ape adenovirus isolates. The Journal of Gene Medicine, 13, 17\u201325.","journal-title":"The Journal of Gene Medicine"},{"key":"159_CR131","first-page":"493","volume":"11","author":"BK Sack","year":"2009","unstructured":"Sack, B. K., & Herzog, R. W. (2009). Evading the immune response upon in vivo gene therapy with viral vectors. Current Opinion in Molecular Therapeutics, 11, 493\u2013503.","journal-title":"Current Opinion in Molecular Therapeutics"},{"key":"159_CR132","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181012","volume":"12","author":"B Saha","year":"2017","unstructured":"Saha, B., & Parks, R. J. (2017). Human adenovirus type 5 vectors deleted of early region 1 (E1) undergo limited expression of early replicative E2 proteins and DNA replication in non-permissive cells. PLoS\u00a0One, 12, e0181012.","journal-title":"PLoS\u00a0One"},{"key":"159_CR133","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1248\/bpb.b21-00394","volume":"44","author":"F Sakurai","year":"2021","unstructured":"Sakurai, F., Tsukamoto, T., Ono, R., Nishimae, F., Shiota, A., Iizuka, S., Shimizu, K., Sakai, E., Ishida, Y., Tateno, C., et al. (2021). Transduction properties of an adenovirus vector containing sequences complementary to a liver-specific microRNA, miR-122a, in the 3\u2032-untranslated region of the E4 gene in human hepatocytes from chimeric mice with humanized liver. Biological and Pharmaceutical Bulletin, 44, 1506\u20131513.","journal-title":"Biological and Pharmaceutical Bulletin"},{"key":"159_CR134","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.jmb.2008.08.054","volume":"383","author":"C San Mart\u00edn","year":"2008","unstructured":"San Mart\u00edn, C., Glasgow, J. N., Borovjagin, A., Beatty, M. S., Kashentseva, E. A., Curiel, D. T., Marabini, R., & Dmitriev, I. P. (2008). Localization of the N-terminus of minor coat protein IIIa in the adenovirus capsid. Journal of Molecular Biology, 383, 923\u2013934.","journal-title":"Journal of Molecular Biology"},{"key":"159_CR135","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3390\/cancers12051295","volume":"12","author":"M Sato-Dahlman","year":"2020","unstructured":"Sato-Dahlman, M., LaRocca, C. J., Yanagiba, C., & Yamamoto, M. (2020). Adenovirus and immunotherapy: Advancing cancer treatment by combination. Cancers, 12, 1295.","journal-title":"Cancers"},{"key":"159_CR136","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021). Therapeutic cancer vaccines. Nature Reviews Cancer, 21, 360\u2013378.","journal-title":"Nature Reviews Cancer"},{"key":"159_CR137","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1089\/104303400750001417","volume":"11","author":"G Schiedner","year":"2000","unstructured":"Schiedner, G., Hertel, S., & Kochanek, S. (2000). Efficient transformation of primary human amniocytes by E1 functions of Ad5: Generation of new cell lines for adenoviral vector production. Human Gene Therapy, 11, 2105\u20132116.","journal-title":"Human Gene Therapy"},{"key":"159_CR138","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.3390\/v14091952","volume":"14","author":"J Scholz","year":"2022","unstructured":"Scholz, J., Weil, P. P., Pembaur, D., Koukou, G., Aydin, M., Hauert, D., Postberg, J., Kreppel, F., & Hagedorn, C. (2022). An adenoviral vector as a versatile tool for delivery and expression of miRNAs. Viruses, 14, 1952.","journal-title":"Viruses"},{"key":"159_CR139","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/2193-1801-2-234","volume":"2","author":"M Schulte","year":"2013","unstructured":"Schulte, M., Sorkin, M., Al-Benna, S., Stupka, J., Hirsch, T., Daigeler, A., Kesting, M. R., Steinau, H. U., Jacobsen, F., & Steinstraesser, L. (2013). Innate immune response after adenoviral gene delivery into skin is mediated by AIM2, NALP3, DAI and mda5. Springerplus, 2, 234.","journal-title":"Springerplus"},{"key":"159_CR140","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1080\/17460441.2020.1765770","volume":"15","author":"M Segal","year":"2020","unstructured":"Segal, M., & Slack, F. J. (2020). Challenges identifying efficacious miRNA therapeutics for cancer. Expert Opinion on Drug Discovery, 15, 987\u2013992.","journal-title":"Expert Opinion on Drug Discovery"},{"key":"159_CR141","doi-asserted-by":"publisher","first-page":"6883","DOI":"10.1074\/jbc.RA117.000347","volume":"293","author":"Y Shao","year":"2018","unstructured":"Shao, Y., Wang, L., Guo, N., Wang, S., Yang, L., Li, Y., Wang, M., Yin, S., Han, H., Zeng, L., et al. (2018). Cas9-nickase-mediated genome editing corrects hereditary tyrosinemia in rats. The Journal of Biological Chemistry, 293, 6883\u20136892.","journal-title":"The Journal of Biological Chemistry"},{"key":"159_CR142","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2174\/157488509788185123","volume":"4","author":"A Sharma","year":"2009","unstructured":"Sharma, A., Tandon, M., Bangari, D. S., & Mittal, S. K. (2009). Adenoviral vector-based strategies for cancer therapy. Current Drug Therapy, 4, 117\u2013138.","journal-title":"Current Drug Therapy"},{"key":"159_CR143","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41417-017-0002-1","volume":"25","author":"PK Sharma","year":"2018","unstructured":"Sharma, P. K., Dmitriev, I. P., Kashentseva, E. A., Raes, G., Li, L., Kim, S. W., Lu, Z. H., Arbeit, J. M., Fleming, T. P., Kaliberov, S. A., et al. (2018). Development of an adenovirus vector vaccine platform for targeting dendritic cells. Cancer Gene Therapy, 25, 27\u201338.","journal-title":"Cancer Gene Therapy"},{"key":"159_CR144","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.omtm.2019.11.001","volume":"15","author":"AR Shaw","year":"2019","unstructured":"Shaw, A. R., & Suzuki, M. (2019). Immunology of adenoviral vectors in cancer therapy. Molecular Therapy Methods & Clinical Development, 15, 418\u2013429.","journal-title":"Molecular Therapy Methods & Clinical Development"},{"key":"159_CR145","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.3390\/ph16101416","volume":"16","author":"AY Shchaslyvyi","year":"2023","unstructured":"Shchaslyvyi, A. Y., Antonenko, S. V., Tesliuk, M. G., & Telegeev, G. D. (2023). Current state of human gene therapy: Approved products and vectors. Pharmaceuticals, 16, 1416.","journal-title":"Pharmaceuticals"},{"key":"159_CR146","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","volume":"28","author":"JL Shirley","year":"2020","unstructured":"Shirley, J. L., de Jong, Y. P., Terhorst, C., & Herzog, R. W. (2020). Immune responses to viral gene therapy vectors. Molecular Therapy, 28, 709\u2013722.","journal-title":"Molecular Therapy"},{"key":"159_CR147","doi-asserted-by":"publisher","first-page":"4125","DOI":"10.1016\/j.vaccine.2011.03.098","volume":"29","author":"JI Sin","year":"2011","unstructured":"Sin, J. I. (2011). MyD88 signal is required for more efficient induction of Ag-specific adaptive immune responses and antitumor resistance in a human papillomavirus E7 DNA vaccine model. Vaccine, 29, 4125\u20134131.","journal-title":"Vaccine"},{"key":"159_CR148","doi-asserted-by":"publisher","first-page":"6492","DOI":"10.1128\/JVI.00557-08","volume":"82","author":"JG Smith","year":"2008","unstructured":"Smith, J. G., Cassany, A., Gerace, L., Ralston, R., & Nemerow, G. R. (2008). Neutralizing antibody blocks adenovirus infection by arresting microtubule-dependent cytoplasmic transport. Journal of Virology, 82, 6492\u20136500.","journal-title":"Journal of Virology"},{"key":"159_CR149","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/B978-012369454-6\/50030-3","volume-title":"American College of Laboratory Animal Medicine, the mouse in biomedical research","author":"KR Spindler","year":"2007","unstructured":"Spindler, K. R., Moore, M. L., & Cauthen, A. N. (2007). Chapter 2\u2014Mouse adenoviruses. In J. G. Fox, M. T. Davisson, F. W. Quimby, S. W. Barthold, C. E. Newcomer, & A. L. Smith (Eds.), American College of Laboratory Animal Medicine, the mouse in biomedical research (2nd ed., pp. 49\u201365). Academic Press.","edition":"2"},{"key":"159_CR150","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1089\/hum.2021.120","volume":"33","author":"E Statkute","year":"2022","unstructured":"Statkute, E., Wang, E. C. Y., & Stanton, R. J. (2022). An optimized CRISPR\/Cas9 adenovirus vector (AdZ-CRISPR) for high-throughput cloning of sgRNA, using enhanced sgRNA and Cas9 variants. Human Gene Therapy, 33, 990\u20131001.","journal-title":"Human Gene Therapy"},{"key":"159_CR151","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3390\/vaccines8020170","volume":"8","author":"T Steffen","year":"2020","unstructured":"Steffen, T., Hassert, M., Hoft, S. G., Stone, E. T., Zhang, J., Geerling, E., Grimberg, B. T., Roberts, M. S., Pinto, A. K., & Brien, J. D. (2020). Immunogenicity and efficacy of a recombinant human adenovirus type 5 vaccine against Zika virus. Vaccines, 8, 170.","journal-title":"Vaccines"},{"key":"159_CR152","doi-asserted-by":"publisher","first-page":"9987","DOI":"10.1128\/JVI.00751-10","volume":"84","author":"SL Stephen","year":"2010","unstructured":"Stephen, S. L., Montini, E., Sivanandam, V. G., Al-Dhalimy, M., Kestler, H. A., Finegold, M., Grompe, M., & Kochanek, S. (2010). Chromosomal integration of adenoviral vector DNA in vivo. Journal of Virology, 84, 9987\u20139994.","journal-title":"Journal of Virology"},{"key":"159_CR153","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/infdis\/jiac445","volume":"227","author":"DJ Stieh","year":"2023","unstructured":"Stieh, D. J., Barouch, D. H., Comeaux, C., Sarnecki, M., Stephenson, K. E., Walsh, S. R., Sawant, S., Heptinstall, J., Tomaras, G. D., Kublin, J. G., et al. (2023). Safety and immunogenicity of Ad26-vectored HIV vaccine with mosaic immunogens and a novel mosaic envelope protein in HIV-uninfected adults: A phase 1\/2a study. The Journal of Infectious Diseases, 227, 939\u2013950.","journal-title":"The Journal of Infectious Diseases"},{"key":"159_CR154","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101530","volume":"25","author":"Y Su","year":"2022","unstructured":"Su, Y., Su, C., & Qin, L. (2022). Current landscape and perspective of oncolytic viruses and their combination therapies. Translational Oncology, 25, 101530.","journal-title":"Translational Oncology"},{"key":"159_CR155","doi-asserted-by":"publisher","first-page":"4392","DOI":"10.1158\/1078-0432.CCR-22-0622","volume":"28","author":"K Sun","year":"2022","unstructured":"Sun, K., Xu, Y., Zhang, L., Niravath, P., Darcourt, J., Patel, T., Teh, B. S., Farach, A. M., Guerrero, C., Mathur, S., et al. (2022). A phase 2 trial of enhancing immune checkpoint blockade by stereotactic radiation and in situ virus gene therapy in metastatic triple-negative breast cancer. Clinical Cancer Research, 28, 4392\u20134401.","journal-title":"Clinical Cancer Research"},{"key":"159_CR156","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2144\/btn-2022-0051","volume":"73","author":"A Syyam","year":"2022","unstructured":"Syyam, A., Nawaz, A., Ijaz, A., Sajjad, U., Fazil, A., Irfan, S., Muzaffar, A., Shahid, M., Idrees, M., Malik, K., et al. (2022). Adenovirus vector system: Construction, history and therapeutic applications. BioTechniques, 73, 297\u2013305.","journal-title":"BioTechniques"},{"key":"159_CR157","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1158\/0008-5472.CAN-04-0637","volume":"64","author":"J Takamizawa","year":"2004","unstructured":"Takamizawa, J., Konishi, H., Yanagisawa, K., Tomida, S., Osada, H., Endoh, H., Harano, T., Yatabe, Y., Nagino, M., Nimura, Y., et al. (2004). Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Research, 64, 3753\u20133756.","journal-title":"Cancer Research"},{"key":"159_CR158","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.3390\/pathogens11101146","volume":"11","author":"EW Tan","year":"2022","unstructured":"Tan, E. W., Abd-Aziz, N., Poh, C. L., & Tan, K. O. (2022a). Engineered oncolytic adenoviruses: An emerging approach for cancer therapy. Pathogens, 11, 1146.","journal-title":"Pathogens"},{"key":"159_CR159","doi-asserted-by":"publisher","first-page":"6453","DOI":"10.1038\/s41467-022-33834-4","volume":"13","author":"TJ Tan","year":"2022","unstructured":"Tan, T. J., Ang, W. X. G., Wang, W. W., Chong, H. S., Tan, S. H., Cheong, R., Chia, J. W. K., Syn, N. L., Shuen, W. H., Ba, R., et al. (2022b). A phase I study of an adenoviral vector delivering a MUC1\/CD40-ligand fusion protein in patients with advanced adenocarcinoma. Nature Communications, 13, 6453.","journal-title":"Nature Communications"},{"key":"159_CR160","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S1473-3099(20)30019-0","volume":"20","author":"MD Tapia","year":"2020","unstructured":"Tapia, M. D., Sow, S. O., Mbaye, K. D., Thiongane, A., Ndiaye, B. P., Ndour, C. T., Mboup, S., Keshinro, B., Kinge, T. N., Vernet, G., et al. (2020). Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in africa: A randomised, observer-blind, placebo-controlled, phase 2 trial. Lancet Infectious Diseases, 20, 719\u2013730.","journal-title":"Lancet Infectious Diseases"},{"key":"159_CR161","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3390\/cells9040953","volume":"9","author":"F Tasca","year":"2020","unstructured":"Tasca, F., Wang, Q., & Gon\u00e7alves, M. (2020). Adenoviral vectors meet gene editing: A rising partnership for the genomic engineering of human stem cells and their progeny. Cells, 9, 953.","journal-title":"Cells"},{"key":"159_CR162","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1146\/annurev.genet.41.110306.130340","volume":"41","author":"G Teng","year":"2007","unstructured":"Teng, G., & Papavasiliou, F. N. (2007). Immunoglobulin somatic hypermutation. Annual Review of Genetics, 41, 107\u2013120.","journal-title":"Annual Review of Genetics"},{"key":"159_CR163","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1089\/hum.2006.17.193","volume":"17","author":"C Thirion","year":"2006","unstructured":"Thirion, C., Lochm\u00fcller, H., Ruzsics, Z., Boelhauve, M., K\u00f6nig, C., Thedieck, C., Kutik, S., Geiger, C., Kochanek, S., Volpers, C., et al. (2006). Adenovirus vectors based on human adenovirus type 19a have high potential for human muscle-directed gene therapy. Human Gene Therapy, 17, 193\u2013205.","journal-title":"Human Gene Therapy"},{"key":"159_CR164","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3390\/v9070186","volume":"9","author":"A Vasou","year":"2017","unstructured":"Vasou, A., Sultanoglu, N., Goodbourn, S., Randall, R. E., & Kostrikis, L. G. (2017). Targeting pattern recognition receptors (PRR) for vaccine adjuvantation: From synthetic PRR agonists to the potential of defective interfering particles of viruses. Viruses, 9, 186.","journal-title":"Viruses"},{"key":"159_CR165","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.3390\/v2091886","volume":"2","author":"F Vetrini","year":"2010","unstructured":"Vetrini, F., & Ng, P. (2010). Gene therapy with helper-dependent adenoviral vectors: Current advances and future perspectives. Viruses, 2, 1886\u20131917.","journal-title":"Viruses"},{"key":"159_CR166","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1073\/pnas.0510565103","volume":"103","author":"S Volinia","year":"2006","unstructured":"Volinia, S., Calin, G. A., Liu, C. G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., et al. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Sciences of the United States of America, 103, 2257\u20132261.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"159_CR167","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021). Safety and efficacy of the ChAdOx1 nCov-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, 397, 99\u2013111.","journal-title":"Lancet"},{"key":"159_CR168","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa1264","volume":"49","author":"C Wang","year":"2021","unstructured":"Wang, C., Cheng, J. K. W., Zhang, Q., Hughes, N. W., Xia, Q., Winslow, M. M., & Cong, L. (2021). Microbial single-strand annealing proteins enable CRISPR gene-editing tools with improved knock-in efficiencies and reduced off-target effects. Nucleic Acids Research, 49, e36.","journal-title":"Nucleic Acids Research"},{"key":"159_CR169","doi-asserted-by":"publisher","first-page":"eade6790","DOI":"10.1126\/sciadv.ade6790","volume":"9","author":"D Wang","year":"2023","unstructured":"Wang, D., Porter, C. E., Lim, B., Rosewell Shaw, A., Robertson, C. S., Woods, M. L., Xu, Y., Biegert, G. G. W., Morita, D., Wang, T., et al. (2023a). Ultralow-dose binary oncolytic\/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies. Science Advvances, 9, eade6790.","journal-title":"Science Advvances"},{"key":"159_CR170","first-page":"1271","volume":"9","author":"GF Wang","year":"2016","unstructured":"Wang, G. F., Qi, B., Tu, L. L., Liu, L., Yu, G. C., & Zhong, J. X. (2016). Construction of adenovirus vectors encoding the lumican gene by gateway recombinant cloning technology. International Journal of Ophthalmology, 9, 1271\u20131275.","journal-title":"International Journal of Ophthalmology"},{"key":"159_CR171","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.3390\/v14122727","volume":"14","author":"WC Wang","year":"2022","unstructured":"Wang, W. C., Sayedahmed, E. E., & Mittal, S. K. (2022). Significance of preexisting vector immunity and activation of innate responses for adenoviral vector-based therapy. Viruses, 14, 2727.","journal-title":"Viruses"},{"key":"159_CR172","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.3390\/v15091801","volume":"15","author":"Y Wang","year":"2023","unstructured":"Wang, Y., & Shao, W. (2023). Innate immune response to viral vectors in gene therapy. Viruses, 15, 1801.","journal-title":"Viruses"},{"key":"159_CR173","doi-asserted-by":"publisher","first-page":"5291","DOI":"10.3390\/cancers15215291","volume":"15","author":"Z Wang","year":"2023","unstructured":"Wang, Z., Sun, P., Li, Z., & Xiao, S. (2023b). Clinical advances and future directions of oncolytic virotherapy for head and neck cancer. Cancers, 15, 5291.","journal-title":"Cancers"},{"key":"159_CR174","first-page":"29","volume":"273","author":"M Windheim","year":"2004","unstructured":"Windheim, M., Hilgendorf, A., & Burgert, H. G. (2004). Immune evasion by adenovirus E3 proteins: Exploitation of intracellular trafficking pathways. Current Topics in Microbiology and Immunology, 273, 29\u201385.","journal-title":"Current Topics in Microbiology and Immunology"},{"key":"159_CR175","volume-title":"Fields' virology","author":"W Wold","year":"2013","unstructured":"Wold, W., & Ison, M. (2013). Adenovirus. In D. M. Knipe & P. M. Howely (Eds.), Fields\u2019 virology. Lippincott, Williams & Wilkins."},{"key":"159_CR176","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2174\/1566523213666131125095046","volume":"13","author":"WS Wold","year":"2013","unstructured":"Wold, W. S., & Toth, K. (2013). Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Current Gene Therapy, 13, 421\u2013433.","journal-title":"Current Gene Therapy"},{"key":"159_CR177","doi-asserted-by":"publisher","first-page":"6739","DOI":"10.1128\/JVI.00652-13","volume":"87","author":"K Wu","year":"2013","unstructured":"Wu, K., Guimet, D., & Hearing, P. (2013). The adenovirus L4\u201333k protein regulates both late gene expression patterns and viral DNA packaging. Journal of Virology, 87, 6739\u20136747.","journal-title":"Journal of Virology"},{"key":"159_CR178","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1080\/21645515.2015.1016674","volume":"11","author":"K Xiang","year":"2015","unstructured":"Xiang, K., Ying, G., Yan, Z., Shanshan, Y., Lei, Z., Hongjun, L., & Maosheng, S. (2015). Progress on adenovirus-vectored universal influenza vaccines. Human Vaccines & Immunotherapeutics, 11, 1209\u20131222.","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"159_CR179","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1089\/hum.2007.016","volume":"18","author":"T Yamaguchi","year":"2007","unstructured":"Yamaguchi, T., Kawabata, K., Koizumi, N., Sakurai, F., Nakashima, K., Sakurai, H., Sasaki, T., Okada, N., Yamanishi, K., & Mizuguchi, H. (2007). Role of MyD88 and TLR9 in the innate immune response elicited by serotype 5 adenoviral vectors. Human Gene Therapy, 18, 753\u2013762.","journal-title":"Human Gene Therapy"},{"key":"159_CR180","doi-asserted-by":"publisher","first-page":"17286","DOI":"10.1073\/pnas.1009823107","volume":"107","author":"T Yamaguchi","year":"2010","unstructured":"Yamaguchi, T., Kawabata, K., Kouyama, E., Ishii, K. J., Katayama, K., Suzuki, T., Kurachi, S., Sakurai, F., Akira, S., & Mizuguchi, H. (2010). Induction of type I interferon by adenovirus-encoded small RNAs. Proceedings of the National Academy of Sciences of the United States of America, 107, 17286\u201317291.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"159_CR181","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/cas.13228","volume":"108","author":"Y Yamamoto","year":"2017","unstructured":"Yamamoto, Y., Nagasato, M., Yoshida, T., & Aoki, K. (2017). Recent advances in genetic modification of adenovirus vectors for cancer treatment. Cancer Science, 108, 831\u2013837.","journal-title":"Cancer Science"},{"key":"159_CR182","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13045-019-0723-8","volume":"12","author":"Y Yang","year":"2019","unstructured":"Yang, Y., Zhang, X., Lin, F., Xiong, M., Fan, D., Yuan, X., Lu, Y., Song, Y., Zhang, Y., Hao, M., et al. (2019). Bispecific CD3\u2013HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells. Journal of Hematology & Oncology, 12, 46.","journal-title":"Journal of Hematology & Oncology"},{"key":"159_CR183","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.bbrc.2007.08.001","volume":"362","author":"X Yao","year":"2007","unstructured":"Yao, X., Yoshioka, Y., Eto, Y., Morishige, T., Okada, Y., Mizuguchi, H., Mukai, Y., Okada, N., & Nakagawa, S. (2007). TERT promoter-driven adenovirus vector for cancer gene therapy via systemic injection. Biochemical and Biophysical Research Communications, 362, 419\u2013424.","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"159_CR184","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1089\/cbr.2006.21.225","volume":"21","author":"Z Ye","year":"2006","unstructured":"Ye, Z., Wang, X., Hao, S., Zhong, J., Xiang, J., & Yang, J. (2006). Oncolytic adenovirus-mediated E1A gene therapy induces tumor-cell apoptosis and reduces tumor angiogenesis leading to inhibition of hepatocellular carcinoma growth in animal model. Cancer Biotherapy & Radiopharmaceuticals, 21, 225\u2013234.","journal-title":"Cancer Biotherapy & Radiopharmaceuticals"},{"key":"159_CR185","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2023.09.004","volume":"34","author":"H Zhang","year":"2023","unstructured":"Zhang, H., Wang, H., An, Y., & Chen, Z. (2023). Construction and application of adenoviral vectors. Molecular Therapy Nucleic Acids, 34, 102027.","journal-title":"Molecular Therapy Nucleic Acids"},{"key":"159_CR186","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/B978-0-12-397833-2.00010-8","volume-title":"Recent advances in cancer research and therapy","author":"SY Zhang","year":"2012","unstructured":"Zhang, S. Y., Lu, Y. Y., & Peng, Z. H. (2012). Recombinant adenoviral-p53 agent (gendicine\u00ae): Quality control, mechanism of action, and its use for treatment of malignant tumors. In X. Y. Liu, S. Pestka, & Y. F. Shi (Eds.), Recent advances in cancer research and therapy (pp. 215\u2013243). Elsevier."},{"key":"159_CR187","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0042-6822(91)90024-6","volume":"180","author":"XL Zhang","year":"1991","unstructured":"Zhang, X. L., Bellett, A. J., Hla, R. T., Braithwaite, A. W., & M\u00fcllbacher, A. (1991). Adenovirus type 5 E3 gene products interfere with the expression of the cytolytic T cell immunodominant E1A antigen. Virology, 180, 199\u2013206.","journal-title":"Virology"},{"key":"159_CR188","doi-asserted-by":"publisher","first-page":"101463","DOI":"10.1016\/j.isci.2020.101463","volume":"23","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y., Ma, Z., Wang, Y., Boyer, J., Ni, G., Cheng, L., Su, S., Zhang, Z., Zhu, Z., Qian, J., et al. (2020). Streptavidin promotes DNA binding and activation of cGAS to enhance innate immunity. iScience, 23, 101463.","journal-title":"iScience"},{"key":"159_CR189","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.virol.2007.02.013","volume":"363","author":"H Zhao","year":"2007","unstructured":"Zhao, H., Granberg, F., & Pettersson, U. (2007). How adenovirus strives to control cellular gene expression. Virology, 363, 357\u2013375.","journal-title":"Virology"},{"key":"159_CR190","doi-asserted-by":"publisher","first-page":"e01085","DOI":"10.1128\/JVI.01085-19","volume":"93","author":"Y Zhao","year":"2019","unstructured":"Zhao, Y., & Karijolich, J. (2019). Know thyself: RIG-I-Like receptor sensing of DNA virus infection. Journal of Virology, 93, e01085-e1119.","journal-title":"Journal of Virology"},{"key":"159_CR191","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.707290","volume":"12","author":"Y Zhao","year":"2021","unstructured":"Zhao, Y., Liu, Z., Li, L., Wu, J., Zhang, H., Zhang, H., Lei, T., & Xu, B. (2021). Oncolytic adenovirus: Prospects for cancer immunotherapy. Frontiers in Microbiology, 12, 707290.","journal-title":"Frontiers in Microbiology"},{"key":"159_CR192","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.omto.2019.10.007","volume":"15","author":"M Zheng","year":"2019","unstructured":"Zheng, M., Huang, J., Tong, A., & Yang, H. (2019). Oncolytic viruses for cancer therapy: Barriers and recent advances. Molecular Therapy Oncolytics, 15, 234\u2013247.","journal-title":"Molecular Therapy Oncolytics"},{"key":"159_CR193","first-page":"1269","volume":"38","author":"L Zhu","year":"2023","unstructured":"Zhu, L., Chen, M., Wang, W., Zhu, J., & Wu, H. (2023). MicroRNA-141-3p mediates epithelial cell proliferation, apoptosis, and epithelial-mesenchymal transition and alleviates pulmonary fibrosis in mice via Spred2. Histology and Histopathology, 38, 1269\u20131282.","journal-title":"Histology and Histopathology"},{"key":"159_CR194","doi-asserted-by":"publisher","first-page":"4336","DOI":"10.1111\/j.1742-4658.2006.05430.x","volume":"273","author":"C Zubieta","year":"2006","unstructured":"Zubieta, C., Blanchoin, L., & Cusack, S. (2006). Structural and biochemical characterization of a human adenovirus 2\/12 penton base chimera. FEBS Journal, 273, 4336\u20134345.","journal-title":"FEBS Journal"},{"key":"159_CR195","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.molcel.2004.11.041","volume":"17","author":"C Zubieta","year":"2005","unstructured":"Zubieta, C., Schoehn, G., Chroboczek, J., & Cusack, S. (2005). The structure of the human adenovirus 2 penton. Molecular Cell, 17, 121\u2013135.","journal-title":"Molecular Cell"}],"container-title":["Journal of Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12275-024-00159-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12275-024-00159-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12275-024-00159-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T17:47:08Z","timestamp":1735062428000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12275-024-00159-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":195,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["159"],"URL":"https:\/\/doi.org\/10.1007\/s12275-024-00159-4","relation":{},"ISSN":["1225-8873","1976-3794"],"issn-type":[{"value":"1225-8873","type":"print"},{"value":"1976-3794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"15 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have no financial conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}